Abstract 4643: Plasma thioredoxin reductase 1 as a diagnostic marker for non-small cell lung cancer

Abstract

Abstract Non-invasive diagnostic markers for patients with suspicious non-small cell lung cancer (NSCLC) may provide needed guidance on invasive diagnostic and therapeutic decisions. Thioredoxin reductase 1 (TrxR1) is a pivotal intracellular redox sensor and antioxidant enzyme, and plays an important part in tumor growth, progression, metastasis, and chemotherapy resistance. The goal of this study is to test the feasibility of developing plasma TrxR1 as a novel diagnostic marker for NSCLC. The plasma TrxR1 activity was determined spectrophotometrically by monitoring the NADPH-dependent production of 2-nitro-5-thiobenzoate at 412nm and at 37°C. All detection kits and automatic analyzer possess independent intellectual property rights, and have been widely used in breast cancer screening. In this study, the plasma levels of TrxR1 were measured in 45 treatment-naïve NSCLC patients and 10 individuals with benign tumor-like pulmonary diseases. Taking plasma TrxR1 activity of 4 as reference, the overall concordance rate was 73.3%, while those of CEA, CA199, CA125, NSE, CYFRA21-1 and SCC were 19.0%, 7.1%, 16.7%, 35.7%, 24.4% and 2.5%, respectively. Furthermore, using TNM staging (AJCC 7th ed.) as classifier, the concordance rates of TrxR1 in local, local regional and advanced stage subgroups were 66.7% (20/30), 77.8% (7/9) and 100% (4/4), respectively. A multipoint linear fitting correlation model was created, and the equation was TrxR1 = 5.821 + 0.396*Stage. Besides, the concordance rates of TrxR1 in benign tumor-like pulmonary diseases was 60% (6/10). Our data suggest that plasma TrxR1 activity is a useful non-invasive diagnostic marker for NSCLC, and there may be a linear correlation between TrxR1 activity and pathological stage. Citation Format: Xiaozheng Kang, Chaoran Dong, Bocun Shen, Wanpu Yan, Liang Dai, Yongbo Yang, Hanwei Yin, Guobing Xu, Huihui Zeng, Ke-Neng Chen. Plasma thioredoxin reductase 1 as a diagnostic marker for non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4643. doi:10.1158/1538-7445.AM2017-4643